SYN News and Press, Synthetic Biologics Inc. From 04/19/22

Has the stock market bottomed? That’s what some traders are weighing right now against a backdrop of new earnings data and Fed speak. Meanwhile, small-caps, micro-caps, and penny stocks remain a hot topic among retail traders. Other than their ability to record significant ga...

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV) platform- ROCKVILLE,...

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallό, Ph.D., appointed as General Director of Synthetic Biologics’ European Subsidiary, transitioning from C...

ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate u...

Synthetic Biologics, Inc. (SYN) Q4 2021 Earnings Conference Call March 16, 2022 16:30 ET CompanyParticipants Chris Calabrese - LifeSci Advisors, IR Steven Shallcross - Chief Executive Officer & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Fran...

Synthetic Biologics press release (NYSE:SYN): FY GAAP EPS of -$0.19 misses by $0.01. As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023. For further details see: Synthetic Biologics GAAP EPS of -$0.19 m...

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway th...

Synthetic Biologics (NYSE:SYN) is scheduled to announce FY earnings results on Wednesday, March 16th, after market close. The consensus EPS Estimate is -$0.10 (+84.8% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downwar...

IDEX, LEN, WSM, PD, CPRX, NBEV, SYN, OTCQX:MRMD, REI, OTCQX:TRSSF, ZTO, ASM, SMTC, GES, LGO, SMTS, BAK, LMB, LFT, EDR, ETON, IMV, PANL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemothera...